About Gap junction beta-2 protein
Gap junction beta-2 protein (GJB2) is a protein
from Homo sapiens identified by UniProt accession
P29033, 226 residues long.
MolForge cross-references it against 0 known binders and
401 disease associations.
Target properties
| Protein name | Gap junction beta-2 protein |
| UniProt accession | P29033 |
| Gene | GJB2 |
| Organism | Homo sapiens |
| Length | 226 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (401)
Diseases linked to this target (Open Targets).
- palmoplantar keratoderma-deafness syndrome · score 0.81
- Bart-Pumphrey syndrome · score 0.78
- keratoderma hereditarium mutilans · score 0.78
- autosomal dominant keratitis-ichthyosis-hearing loss syndrome · score 0.77
- autosomal dominant nonsyndromic hearing loss 3A · score 0.77
- Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome · score 0.74
- autosomal dominant nonsyndromic hearing loss · score 0.72
- hearing loss, autosomal recessive · score 0.71
- deafness · score 0.71
- hearing loss · score 0.68
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P29033-F1 | alphafold | PREDICTED | 86.18 | — |
Amino-acid sequence (226 residues)
MDWGTLQTIL GGVNKHSTSI GKIWLTVLFI FRIMILVVAA KEVWGDEQAD FVCNTLQPGC KNVCYDHYFP ISHIRLWALQ LIFVSTPALL VAMHVAYRRH EKKRKFIKGE IKSEFKDIEE IKTQKVRIEG SLWWTYTSSI FFRVIFEAAF MYVFYVMYDG FSMQRLVKCN AWPCPNTVDC FVSRPTEKTV FTVFMIAVSG ICILLNVTEL CYLLIRYCSG KSKKPV
Explore Gap junction beta-2 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets